AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05737212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
Description: Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
Study NCT05737212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq
Description: Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
Study NCT05737212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq
Description: Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours. Thereafter, patient will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
Study NCT05353127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CPET/Cardiopulmonary Exercise Test
Description: During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
Study NCT05021731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin plus Isoniazid
Description: Administration of rifampicin plus isoniazid for latent tuberculosis
Study NCT05021731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine plus Isoniazid
Description: Administration of rifapentine plus isoniazid for latent tuberculosis
Study NCT05021731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin alone
Description: Administration of rifampicin alone for latent tuberculosis
Study NCT04652830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Naprapathy training
Description: Active training aimed at strengthening the abdominal muscles
Study NCT04652830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No change of daily routines in regard to training
Study NCT05858437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Study NCT05858437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Study NCT04807400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
Study NCT04807400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural Support
Description: Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
Study NCT06463353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trilinolein cream group
Description: Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
Study NCT06463353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cream base group
Description: Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
Study NCT04789694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological intervention
Description: * Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring
Study NCT04789694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: * Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support
Study NCT04789694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: * Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation
Study NCT04911179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.
Description: The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant.
Study NCT05110313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILDRAKIZUMAB
Description: ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle.
Study NCT04879394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
Study NCT05757947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Сoronary bypass surgery according to the I-graft method
Description: Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft.
Study NCT05757947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Сoronary bypass surgery by the method of free conduit
Description: Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta.
Study NCT05266755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fracture Territorial Liaison Service afert a Hip fracture
Description: Give a diferent than the current one way of follow up to the patients with hip fracture
Study NCT05266755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fracture Territorial Liaison Service afert a Hip fracture
Description: Give a diferent than the current one way of follow up to the patients with hip fracture
Study NCT05023187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCOT
Description: A 8-week social and cognitive online training to improve both cognitive and social functioning, which includes 2 sessions (\~45 minutes each) of individual cognitive training through the BrainHQ© program 2020 (BrainHQ© Posit Science) and a psycho-educational group session for each week (24 sessions in total).~In the experimental intervention, all activities are focused on enhancing executive functions (working memory, processing speed, inhibitory control etc.) and social cognition abilities (identifying/recognizing facial expressions, styles attribution, drawing conclusions etc.).
Study NCT04807400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Support
Description: Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
Study NCT04807400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background lipid lowering therapy
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Study NCT04807400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background lipid lowering therapy
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Study NCT05110495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
Study NCT05023187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics.
Study NCT04699708 — intervention group
Intervention type: DEVICE
Intervention: Carbon dioxide monitoring
Description: Blinded recording of CO2 during preterm resuscitation.
Study NCT05888246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
Study NCT06633627 — intervention group
Intervention type: OTHER
Intervention: Recording of brain activity using electroencephalography (EEG)
Description: Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
Study NCT04977479 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
Study NCT04977479 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
Study NCT04977479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
Study NCT04977479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
Study NCT04977479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
Study NCT04977479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Description: mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
Study NCT05718895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-022
Description: Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design.
Study NCT05052476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bactecal® D Liquid
Description: The patients will be randomized into two arms, A and B, in function of the intervention dose
Study NCT06582498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active intervention
Description: This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.
Study NCT06582498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity intervention
Description: This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
Study NCT06418516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule-sponge
Description: The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
Study NCT04625244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video assisted home therapy
Description: Subjects will follow along with prerecorded therapy videos.
Study NCT05019950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIM-1324
Description: Once daily oral tablet
Study NCT06333535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: foot massage
Study NCT06333535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage
Description: abdominal massage
Study NCT06333535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot and abdominal massage
Description: foot and abdominal massage
Study NCT05601986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board.
Study NCT05601986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board.
Study NCT05601986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
Study NCT06275594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byfavo
Description: For induction and maintenance of sedation
Study NCT06275594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study NCT04896320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
Study NCT06397352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker®
Description: All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
Study NCT06397352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy® Group
Description: All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
Study NCT06113133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of oxygen uptake
Description: oxygen uptake is obtained during a maximal exercise test
Study NCT05351268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioactive seed brachytherapy
Description: The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
Study NCT05773820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJB001
Description: Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.
Study NCT04877470 — intervention group
Intervention type: OTHER
Intervention: Consultation at spine-centre
Description: All patients who visited the spine-centre for the first time in 2019 are included in this group.
Study NCT06063577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix suture
Description: Stratafix symmetric suture
Study NCT06063577 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care suture
Description: Standard of care suture
Study NCT04777695 — intervention group
Intervention type: OTHER
Intervention: Decibel Monitor
Description: Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
Study NCT06064474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High ventilation breathwork with retention (HVBR)
Description: Intervention